Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
By Elana Gotkine HealthDay Reporter
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open.
Omer S. Ashruf, from Northeast Ohio Medical University in Rootstown, and colleagues conducted a retrospective cohort study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA versus metformin and insulin. The study included patients with T2D prescribed a GLP-1 RA, insulin, or metformin between April 30, 2005, and Oct. 31, 2023 (51,617; 611,115; and 938,602 patients, respectively). Groups were independently matched using a nearest neighbor greedy matching algorithm; 47,716 patients were included in the GLP-1 RA-insulin analysis and 50,590 were included in the GLP-1 RA-metformin analysis.
The researchers found that GLP-1 RA use was associated with significantly lower risks for of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared with metformin (hazard ratios, 0.61 and 0.67, respectively). No significant difference was seen in the risk for any other hematologic cancer. GLP-1 RA use was associated with significantly lower risks for myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma, MDS, MPN, monoclonal gammopathy, multiple myeloma, and amyloidosis compared with insulin (hazard ratios, 0.39, 0.45, 0.42, 0.19, 0.50, 0.68, 0.49, and 0.52, respectively). GLP-1 RA use was associated with a 54 percent lower risk than that seen with insulin across all hematologic cancers.
"The findings of this cohort study suggest that GLP-1 RAs are associated with reduced risk of developing several hematologic cancers, particularly MDS and MPN, in patients with T2D," the authors write.
One author disclosed ties to Celegene, BMS, and Carobou.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Three Healthy Dietary Patterns Lower Incidence of Type 2 Diabetes Across Ethnicities
THURSDAY, July 31, 2025 -- Three of the most widely studied healthy dietary patterns are associated with lower incidence of type 2 diabetes (T2D), regardless of an individual's...
COVID-19 Vaccine Boosters Aid Outcomes in Patients With Cancer
TUESDAY, July 29, 2025 -- COVID-19 vaccination boosters protect people with cancer developing from severe COVID-19, according to a study published online July 17 in JAMA...
Prediabetes Risk Doubled for Asian, Pacific Islander Teens With Overweight, Obesity
TUESDAY, July 29, 2025 -- Among adolescents with overweight or obesity, prediabetes is more than twice as common in Asian and Pacific Islander (Asian/PI) adolescents than in White...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.